{
  "title": "Evaluation and Management of Unresectable Hepatocellular Carcinoma: Multidisciplinary Indian Consensus Statements from a Delphi PanelGlobal Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesComprehensive review of hepatocellular carcinoma in India: current challenges and future directionsLiver transplantation beyond Milan CriteriaAtezolizumab plus bevacizumab in unresectable hepatocellular carcinomaTremelimumab plus durvalumab in unresectable hepatocellular carcinomaLenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialBCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateDevelopment of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinomaTransarterial chemoembolization and (90)Y radioembolization for hepatocellular carcinoma: review of current applications beyond intermediate-stage diseaseTACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysisLiver resection for HCC outside the BCLC criteriaLiving donor liver transplantation for hepatocellular carcinoma in Indian patients- is the scenario different?Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelinesThe importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinomaA global view of hepatocellular carcinoma: trends, risk, prevention and managementReview article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairmentAlbumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinomaThe ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinomaIndependent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinomaGreen light for liver function monitoring using indocyanine green? An overview of current clinical applicationsPreoperative assessment of liver function: a comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance testAssessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resectionUse of liver stiffness measurement for liver resection surgery: correlation with indocyanine green clearance testing and post-operative outcomeValue of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinomaEASL clinical practice guidelines: management of hepatocellular carcinomaPalliative care in hepatocellular carcinomaClinical profile, patterns of care & adherence to guidelines in patients with hepatocellular carcinoma: prospective multi-center studyExperience with changing etiology and nontransplant curative treatment modalities for hepatocellular carcinoma in a real-life setting-a retrospective descriptive analysisHepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapyHepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrenceTenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: a systematic review and meta-analysis\nEASL recommendations on treatment of hepatitis C: final update of the series\nDirect-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinomaDirect-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort studyHow much remnant is enough in liver resection?The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic reviewSelection criteria for hepatectomy in patients with hepatocellular carcinoma classified as Child-Pugh class BStrategies for safer liver surgery and partial liver transplantationPortal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysisOutcome of partial hepatectomy for large (> 10\u2009cm) hepatocellular carcinomaOutcomes of hepatic resection for huge hepatocellular carcinoma (\u2265 10\u2009cm in diameter)Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide surveySurvival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasionA new classification for hepatocellular carcinoma with hepatic vein tumor thrombusSurgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a Korean multicenter studyBile duct thrombi in hepatocellular carcinoma: is aggressive surgery worthwhile?Liver resection for multiple hepatocellular carcinomas: a Japanese nationwide surveyLiver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: a multicenter analysis of 1,066 patientsAdjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinomaDownstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapyTransarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews [Internet]The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) for patients with medium-to-large hepatocellular carcinoma: a retrospective analysis of long-term outcomeTranscatheter arterial chemoembolization with or without radiofrequency ablation: outcomes in patients with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma\nConventional\n\ndrug-eluting beads transarterial chemoembolization for hepatocellular carcinoma\nProspective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V studyTransarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysisPersonalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trialSequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinomaLong-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinomaRandomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysisProton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trialA phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacyNRG/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC) ()Combination transarterial chemoembolization and stereotactic body radiation therapy for unresectable single large hepatocellular carcinoma: results from a prospective phase 2 trialStereotactic radiotherapy after incomplete transarterial (Chemo-) embolization (TAE) versus exclusive TAE or TACE for treatment of inoperable HCC: a phase III trial ()Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trialNeoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled studySorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trialRandomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trialFinal results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinomaLenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)Management of hepatocellular carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 UpdateEfficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trialSIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinomaImpact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinomaAnalysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: a multicenter analysis\nSorafenib\n\n. lenvatinib as first-line therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis\nSorafenib in advanced hepatocellular carcinomaEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialSurvival of trial-like and non-trial-like patients with immunotherapy in advanced hepatocellular carcinoma in real world: a collaborative multicenter Indian study (IMHEP)Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinomaAtezolizumab/bevacizumab vs. lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center studyAtezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide populationNivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialPembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trialCheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosisSorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialCabozantinib in patients with advanced and progressing hepatocellular carcinomaRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialRamucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialEfficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial",
  "pmcid": "12714441",
  "features": {
    "sample_size": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "randomization": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "blinding": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "allocation_concealment": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "interaction_subgroup": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "variable_definitions": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "analysis_principles": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "itt_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "software": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "error_measures": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "multiplicity_correction": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "normality_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "p_values": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "confidence_intervals": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "comparative_stats": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "non_parametric": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "assumption_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "survival_analysis": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "regression_and_models": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "reporting_guidelines": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "data_types": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "dependency": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "clustering": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "missing_data": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "effect_size": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "post_hoc": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "baseline_reporting": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling_extra": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "systematic_review_metrics": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "diagnostic_metrics": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "model_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "domain_indicators": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    }
  },
  "feedback": {
    "overall_score": 7.0,
    "rigor_rating": "Medium",
    "critical_gaps": [
      {
        "message": "Sample size justification lacks explicit power calculation details.",
        "evidence": "No direct quote found."
      },
      {
        "message": "Reporting of blinding or masking procedure is missing.",
        "evidence": "No matches for 'blinded' or 'masked'"
      }
    ],
    "strengths": [],
    "actionable_recommendations": [
      {
        "item": "Sample Size",
        "issue": "No power calculation found.",
        "recommendation": "Provide alpha, power, and effect size parameters.",
        "source_text": "No matches for 'power' or 'sample size calculation'"
      }
    ],
    "deterministic_audit": true
  }
}